person · Reporting owner
Viehbacher Christopher
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 08, 2019 | May 08, 2019 |
| BIOGEN INC.BIIB · Entity 1675 | Director · President and CEO | February 13, 2026 | February 18, 2026 |
| Braveheart Bio, Inc.BRVE · Entity 4564 | Director | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 08, 2019 · Filed May 08, 2019
This filing explicitly reported no securities owned.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 38,015 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 38,015 · Balance 38,015 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Braveheart Bio, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 609,519 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 83,333 · Balance 609,519 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-08-04 | Direct | 30,000 |
Reported balance
After 2026-08-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-05 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy CAV FAMILY LLC | 150,338 |
Reported balance
Holding disclosure · report date 2026-08-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 150,338 F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F2: The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 20:31 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | PurchaseCommon Stock | 83,333 | $18.00 | $1,499,994.00 |
DisclosureSEC source: 0001470831-26-000801 · wk-form4_1786134672.xml · nonDerivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609,519 Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:31 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000801 · wk-form4_1786134672.xml · derivative · entry 3 Viehbacher Christopher · CIK 0001774478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-08-04 F2 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:18 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 38,015 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000035 · form4.xml · derivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,015 Underlying: Common Stock · 38,015 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 15,453 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000024 · form4.xml · derivative · entry 6 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,907 Underlying: Common Stock · 15,453 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 9,008 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000024 · form4.xml · derivative · entry 5 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,009 Underlying: Common Stock · 9,008 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 6,624 | $201.18 | $1,332,616.32 |
DisclosureSEC source: 0000875045-26-000024 · form4.xml · nonDerivative · entry 4 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,924 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 15,453 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000024 · form4.xml · nonDerivative · entry 3 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 4,356 | $201.18 | $876,340.08 |
DisclosureSEC source: 0000875045-26-000024 · form4.xml · nonDerivative · entry 2 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,095 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 9,008 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000024 · form4.xml · nonDerivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 7,040 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-25-000052 · form4.xml · derivative · entry 3 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: Each RSU vested on the third anniversary of the grant date of December 1, 2022. F2 · derivative.expiration_date: Each RSU vested on the third anniversary of the grant date of December 1, 2022. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 3,404 | $177.78 | $605,163.12 |
DisclosureSEC source: 0000875045-25-000052 · form4.xml · nonDerivative · entry 2 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,443 Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 7,040 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-25-000052 · form4.xml · nonDerivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 9,008 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003962 · form4.xml · derivative · entry 4 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,017 Underlying: Common Stock · 9,008 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 3,201 | $141.35 | $452,461.35 |
DisclosureSEC source: 0001127602-25-003962 · form4.xml · nonDerivative · entry 2 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,807 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 9,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003962 · form4.xml · nonDerivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:55 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 46,360 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003962 · form4.xml · derivative · entry 3 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,360 Underlying: Common Stock · 46,360 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 00:56 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 27,025 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004302 · form4.xml · derivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,025 Underlying: Common Stock · 27,025 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 45,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026909 · form4.xml · derivative · entry 3 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,998 Underlying: Common Stock · 45,998 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_date: This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. F4 · derivative.expiration_date: This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 7,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026909 · form4.xml · derivative · entry 2 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,040 Underlying: Common Stock · 7,040 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022. F3 · derivative.expiration_date: Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantStock Option · Derivative | 80,522 | $0.00 Strike: $301.85 | $0.00 |
DisclosureSEC source: 0001127602-22-026909 · form4.xml · derivative · entry 1 Viehbacher Christopher · CIK 0001774478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,522 Underlying: Common Stock · 80,522 shares Expires 2032-12-01 F1 · derivative.exercise_date: The Stock Options are eligible to vest and become exercisable in approximately equal annual installments on the first, second and third anniversaries of the grant date of December 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.